ClinicalTrials.gg
CompletedNCT00097357Updated Mar 2, 2010

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

A Phase 2/3 interventional study of Apixaban and Enoxaparin in Venous Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 148 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2010-03-02.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,238
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
9th of 26
1,238 · median 445
Started
2004
the only one that year
Phase 2/3
2 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 9th largest by enrollment, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 1st registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.

03

Conditions studied

  • Venous Thrombosis
  • Pulmonary Embolism

Keywords

  • Prevention of deep vein thrombosis and pulmonary embolism
  • Preventive therapy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing elective unilateral total knee replacement surgery.
  • Willing and able to undergo bilateral ascending contrast venography.
  • Able to inject (by self or caregiver) study medication subcutaneously.

Exclusion criteria

Exclusion Criteria:

  • Women of .
  • Women who are pregnant or breastfeeding.
  • Under some conditions, subjects weighing more than 300 lbs. (136kg) and/or (BMI) >=35 kg/m2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,238 participants (actual)

Study arms

  • Experimental
    A1

    Apixaban: 2.5 mg, BID PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Experimental
    A2

    Apixaban: 5 mg, BID PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Experimental
    A3

    Apixaban: 10 mg, BID PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Experimental
    A4

    Apixaban: 5 mg, QD PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Experimental
    A5

    Apixaban: 10 mg, QD PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Experimental
    A6

    Apixaban: 20 mg, QD PLUS Enoxaparin Placebo

    Drug: Apixaban · Drug: Enoxaparin Placebo

  • Active comparator
    E1

    Enoxaparin: 30 mg PLUS Apixaban Placebo

    Drug: Enoxaparin · Drug: Apixaban Placebo

  • Active comparator
    W1

    Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0

    Drug: Warfarin

Interventions

  • Tablets, Oral, 12 +/- 2 days

    Also known as: BMS-562247

  • Injection, SQ, Q12H, 12 +/- 2 days

  • Tablets, Oral, QD, 12 +/- 2 days

  • DrugEnoxaparin Placebo

    Injection, SQ, BID, 12 +/- 2 days

  • DrugApixaban Placebo

    Tablets, Oral, BID, 12 +/- 2 days

06

What researchers measure

Primary outcomes

  1. Determine the dose-response relationship among the 3 QD and 3 BID doses of BMS-562247 on the composite endpoint of adjudicated VTE events and all-cause death in subjects treated with study medication for 12 +/-2 days following surgery

    Time frame: throughout the study

Secondary outcomes

  1. Assess the effect of QD and BID dose of BMS-562247 vs subcutaneous 30 mg q12h enoxaparin and warfarin on the composite endpoint of adjudication VTE events and all-cause death in subjects treated for 12 +/-2 days following surgery

    Time frame: throughout the study

  2. Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated major bleeding events in subjects treated with study medication for 12 +/-2 days following surgery

    Time frame: throughout the study

  3. Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated minor bleeding events in subjects treated with study medication for 12 +/-2 days following surgery

    Time frame: throughout the study

  4. To determine the pharmacokinetic (PK) profile of BMS-562247 and the relationship to dose and dose schedule

    Time frame: throughout the study

07

Study locations

148 sites
  • Local Institution
    Birmingham, Alabama, United States
  • Local Institution
    Mobile, Alabama, United States
  • Local Institution
    Northport, Alabama, United States
  • Local Institution
    Phoenix, Arizona, United States
  • Local Institution
    Scottsdale, Arizona, United States
  • Local Institution
    Tucson, Arizona, United States
  • Local Institution
    Little Rock, Arkansas, United States
  • Local Institution
    Beverly Hills, California, United States
  • Local Institution
    Encinitas, California, United States
  • Local Institution
    Fountain Valley, California, United States
  • Local Institution
    La Jolla, California, United States
  • Local Institution
    La Mesa, California, United States
  • Local Institution
    Long beach, California, United States
  • Local Institution
    Montclair, California, United States
  • Local Institution
    Oakland, California, United States
  • Local Institution
    Pasadena, California, United States
  • Local Institution
    Sacramento, California, United States
  • Local Institution
    San Bernardino, California, United States
  • Local Institution
    San Diego, California, United States
  • Local Institution
    Santa Monica, California, United States
  • Local Institution
    Torrance, California, United States
  • Local Institution
    Wildomar, California, United States
  • Local Institution
    Yuba City, California, United States
  • Local Institution
    Aurora, Colorado, United States
  • Local Institution
    Denver, Colorado, United States
  • Local Institution
    Hartford, Connecticut, United States
  • Local Institution
    Bay Pines, Florida, United States
  • Local Institution
    Brandon, Florida, United States
  • Local Institution
    Clearwater, Florida, United States
  • Local Institution
    Deland, Florida, United States
  • Local Institution
    Ft. Myers, Florida, United States
  • Local Institution
    Hollywood, Florida, United States
  • Local Institution
    Melbourne, Florida, United States
  • Local Institution
    Pensacola, Florida, United States
  • Local Institution
    Sarasota, Florida, United States
  • Local Institution
    St. Petersburg, Florida, United States
  • Local Institution
    Tallahassee, Florida, United States
  • Local Institution
    Winter Park, Florida, United States
  • Local Institution
    Atlanta, Georgia, United States
  • Local Institution
    Cumming, Georgia, United States
  • Local Institution
    Decatur, Georgia, United States
  • Local Institution
    Suwanee, Georgia, United States
  • Local Institution
    Boise, Idaho, United States
  • Local Institution
    Meridian, Idaho, United States
  • Local Institution
    Galesburg, Illinois, United States
  • Local Institution
    Springfield, Illinois, United States
  • Local Institution
    Wichita, Kansas, United States
  • Local Institution
    Lexington, Kentucky, United States
  • Local Institution
    Madisonville, Kentucky, United States
  • Local Institution
    Covington, Louisiana, United States
  • Local Institution
    Baltimore, Maryland, United States
  • Local Institution
    Newton, Massachusetts, United States
  • Local Institution
    Port Huron, Michigan, United States
  • Local Institution
    Jackson, Mississippi, United States
  • Local Institution
    Buffalo, New York, United States
  • Local Institution
    Charlotte, North Carolina, United States
  • Local Institution
    Monroe, North Carolina, United States
  • Local Institution
    Cincinnati, Ohio, United States
  • Local Institution
    Youngstown, Ohio, United States
  • Local Institution
    Tulsa, Oklahoma, United States
  • Local Institution
    Havertown, Pennsylvania, United States
  • Local Institution
    Philadelphia, Pennsylvania, United States
  • Local Institution
    Pittsburgh, Pennsylvania, United States
  • Local Institution
    Charleston, South Carolina, United States
  • Local Institution
    Austin, Texas, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Houston, Texas, United States
  • Local Institution
    Lubbock, Texas, United States
  • Local Institution
    San Antonio, Texas, United States
  • Local Institution
    Newport News, Virginia, United States
  • Local Institution
    Seattle, Washington, United States
  • Local Institution
    Marshfield, Wisconsin, United States
  • Local Institution
    CAPITAL fEDERAL, Buenos Aires, Argentina
  • Local Institution
    Prov. Buenos Aires, Buenos Aires, Argentina
  • Local Institution
    Ciudad De Mendoza, Mendoza, Argentina
  • Local Institution
    Godoy Cruz, Mendoza, Argentina
  • Local Institution
    Buenos Aires, Argentina
  • Local Institution
    Camperdown, New South Wales, Australia
  • Local Institution
    Chermside, Queensland, Australia
  • Local Institution
    Gold Coast, Queensland, Australia
  • Local Institution
    Herston, Queensland, Australia
  • Local Institution
    Bedford Park, South Australia, Australia
  • Local Institution
    Box Hill, Victoria, Australia
  • Local Institution
    Clayton, Victoria, Australia
  • Local Institution
    East Ringwood, Victoria, Australia
  • Local Institution
    Geelong, Victoria, Australia
  • Local Institution
    Windsor, Victoria, Australia
  • Local Institution
    Calgary, Alberta, Canada
  • Local Institution
    Edmonton, Alberta, Canada
  • Local Institution
    Red Deer, Alberta, Canada
  • Local Institution
    Kelowna, British Columbia, Canada
  • Local Institution
    Vancouver, British Columbia, Canada
  • Local Institution
    Dartmouth, Nova Scotia, Canada
  • Local Institution
    Ajax, Ontario, Canada
  • Local Institution
    Burlington, Ontario, Canada
  • Local Institution
    Newmarket, Ontario, Canada
  • Local Institution
    Niagara Falls, Ontario, Canada
  • Local Institution
    Oakville, Ontario, Canada
  • Local Institution
    Richmond Hill, Ontario, Canada
  • Local Institution
    St. Catharines, Ontario, Canada

Showing the first 100 of 148 sites across 9 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2004
First posted
Nov 23, 2004
Start
Oct 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Results delay requested
Feb 27, 2010
Last update
Mar 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00097357
First posted
Nov 23, 2004
Start date
Oct 2004
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Mar 2, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion